12780 El Camino Real, Suite #302
9 articles with Seragon Pharmaceuticals
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
Seragon Announces GenomeScore™, the First AI Platform to Measure Rate of Aging and Physiological Changes
The novel algorithms combine epigenetic and transcriptome analyses to reveal how a person ages in different areas, and opens a door to personalized medicine in the future
Seragon Pharmaceuticals announces GenomeScore™, an AI platform to predict speed of aging and physiological changes
Seragon Pharmaceuticals, Inc., a southern California biopharmaceutical company, announces GenomeScore™ platform, a neural network-trained algorithm combining epigenetic and transcriptome analysis to predict individuals' aging speed and assessing aspects of physiological functions.
Metracrine, based in San Diego, completed a Series C financing round worth $65 million.
Seragon Pharmaceuticals Appoints Debasish Roychowdhury, M.D. To Its Clinical And Scientific Advisory Board And As Acting Chief Medical Officer